During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) ...